Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation Study of Novel Point-of-Care Tests for Infliximab, Adalimumab and C-Reactive Protein in Capillary Blood and Calprotectin in Faeces in an Ambulatory Inflammatory Bowel Disease Care Setting.
Volkers A, Löwenberg M, Braad M, Abeling Y, Gecse K, Berkers N, Montazeri N, D'Haens G. Volkers A, et al. Among authors: lowenberg m. Diagnostics (Basel). 2023 May 12;13(10):1712. doi: 10.3390/diagnostics13101712. Diagnostics (Basel). 2023. PMID: 37238198 Free PMC article.
Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.
Straatmijer T, van Schaik FDM, Bodelier AGL, Visschedijk M, de Vries AC, Ponsioen CY, Pierik M, van Bodegraven AA, West RL, de Boer NKH, Srivastava N, Romkens TEH, Hoekstra J, Oldenburg B, Dijkstra G, van der Woude JC, Löwenberg M, Mujagic Z, Biemans VBC, van der Meulen-de Jong AE, Duijvestein M. Straatmijer T, et al. Among authors: lowenberg m. Aliment Pharmacol Ther. 2023 Jan;57(1):117-126. doi: 10.1111/apt.17248. Epub 2022 Oct 25. Aliment Pharmacol Ther. 2023. PMID: 36282200 Free PMC article.
The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study.
Amiot A, Rahier JF, Baert F, Nahon S, Hart A, Viazis N, Biancone L, Domenech E, Reenears C, Peyrin-Biroulet L, Beaugerie L, Burisch J; I-CARE collaborator group. Amiot A, et al. J Crohns Colitis. 2023 Jan 27;17(1):37-48. doi: 10.1093/ecco-jcc/jjac091. J Crohns Colitis. 2023. PMID: 35767639 Free PMC article.
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes.
Vermeire S, Hanzel J, Löwenberg M, Ferrante M, Bossuyt P, Hoentjen F, Franchimont D, Palatka K, Peeters H, Mookhoek A, de Hertogh G, Molnár T, van Moerkercke W, Lobatón T, Clasquin E, Hulshoff MS, Baert F, D'Haens G; LOVE-UC study group. Vermeire S, et al. Among authors: lowenberg m. J Crohns Colitis. 2024 Apr 23;18(4):540-547. doi: 10.1093/ecco-jcc/jjad179. J Crohns Colitis. 2024. PMID: 37934813
Therapeutic modulation of signal transduction pathways.
Löwenberg M, Peppelenbosch MP, Hommes DW. Löwenberg M, et al. Inflamm Bowel Dis. 2004 Feb;10 Suppl 1:S52-7. doi: 10.1097/00054725-200402001-00011. Inflamm Bowel Dis. 2004. PMID: 15168832 Review. No abstract available.
172 results